Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SNS 01

Next Previous
Drug Profile

SNS 01

Alternative Names: SNS 101; SNS-01; SNS-01-T

Latest Information Update: 04 Jan 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Senesco Technologies
  • Developer Senesco Technologies; Sevion Therapeutics
  • Class Antineoplastics; Gene therapies; Small interfering RNA
  • Mechanism of Action Apoptosis stimulants; Cell adhesion molecule inhibitors; Eukaryotic initiation factor 5A modulators; NF-kappa B inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Multiple myeloma; Diffuse large B cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Diffuse large B cell lymphoma; Lung cancer; Mantle-cell lymphoma; Multiple myeloma

Most Recent Events

  • 17 Nov 2014 Suspended - Phase-I/II for Diffuse large B cell lymphoma (Second-line therapy or greater) in South Africa (IV)
  • 17 Nov 2014 Suspended - Phase-I/II for Diffuse large B cell lymphoma (Second-line therapy or greater) in USA (IV)
  • 17 Nov 2014 Suspended - Phase-I/II for Mantle cell lymphoma (Second-line therapy or greater) in South Africa (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top